XYLT2 and mesothelioma: Given that FGF2 high expression in mesothelioma is one of the critical prognosis factors and carcinogenesis often renders developmental program (Perantoni et al., 1995; Dudley et al., 1999; Schelch et al., 2018), we speculate that targeting therapy for the FGF2 and its downstream, such as Spry2 (García-Domínguez et al., 2011), Ras (Ichise et al., 2014), or Sos (Tan et al., 2020), may be critical for controlling FGF2high+ mesothelioma expansion and metastasis.